CONSUMER goods giant, Reckitt Benckiser (RB) and Founders Factory have launched Founders Factory Hygiene and Home, a joint venture (JV) on Monday (5).
The JV aims to discover and develop startups who will transform the lives of consumers and create a cleaner world through cutting edge technology and innovation.
The FTSE 100 business said it intended to build 10 new start-ups “from scratch” in the business incubator, as well as bringing in 25 existing firms to support them to grow.
The JV will assist the entrepreneurs in creating new clean and safe home products, including businesses aimed at pet care, gardens, hygiene, and others.
RB joins the Founders Family as its eighth corporate partner and will invest in a number of fast-growth start-ups sourced through Founders Factory’s global network.
The JV will give RB access to developing technologies, disruptive business models and entrepreneurial thinking to help them unlock exciting innovation to serve consumers.
Founders Factory is focused on launching and growing start-ups across a range of sectors.
Co-founded by Brent Hoberman, Henry Lane Fox and George Northcott in 2015, Founders Factory has built and scaled over 100 start-ups in its London, Johannesburg and Paris hubs via its unique corporate-backed accelerator and studio model.
Henry Lane Fox, Co-Founder and Executive Chairman, Founders Factory said: "We are very excited to partner with RB to help the most ambitious entrepreneurs build and scale new startups within the hygiene and home sector. Our 70 strong team of digital operators together with the experts at RB, will provide unparalleled opportunities for entrepreneurs exploring new technologies that create cleaner and safer home environments.
"After 100 investments over the past three years across several sectors, we have a proven model to provide rapid growth opportunities for startups and encourage any founder keen to take their business to the next level, to get in touch."
Start-ups selected for Founders Factory Hygiene and Home will have access to RB’s unique market insights into products designed to protect and enhance the lives of consumers.
UK life sciences sector contributed £17.6bn GVA in 2021 and supports 126,000 high-skilled jobs.
Inward life sciences FDI fell by 58 per cent from £1,897m in 2021 to £795m in 2023.
Experts warn NHS underinvestment and NICE pricing rules are deterring innovation and patient access.
Investment gap
Britain is seeking to attract new pharmaceutical investment as part of its plan to strengthen the life sciences sector, Chancellor Rachel Reeves said during meetings in Washington this week. “We do need to make sure that we are an attractive place for pharmaceuticals, and that includes on pricing, but in return for that, we want to see more investment flow to Britain,” Reeves told reporters.
Recent ABPI report, ‘Creating the conditions for investment and growth’, The UK’s pharmaceutical industry is integral to both the country’s health and growth missions, contributing £17.6 billion in direct gross value added (GVA) annually and supporting 126,000 high-skilled jobs across the nation. It also invests more in research and development (R&D) than any other sector. Yet inward life sciences foreign direct investment (FDI) fell by 58per cent, from £1,897 million in 2021 to £795 million in 2023, while pharmaceutical R&D investment in the UK lagged behind global growth trends, costing an estimated £1.3 billion in lost investment in 2023 alone.
Richard Torbett, ABPI Chief Executive, noted “The UK can lead globally in medicines and vaccines, unlocking billions in R&D investment and improving patient access but only if barriers are removed and innovation rewarded.”
The UK invests just 9% of healthcare spending in medicines, compared with 17% in Spain, and only 37% of new medicines are made fully available for their licensed indications, compared to 90% in Germany.
Expert reviews
Shailesh Solanki, executive editor of Pharmacy Business, pointed that “The government’s own review shows the sector is underfunded by about £2 billion per year. To make transformation a reality, this gap must be closed with clear plans for investment in people, premises and technology.”
The National Institute for Health and Care Excellence (NICE) cost-effectiveness threshold £20,000 to £30,000 per Quality-Adjusted Life Year (QALY) — has remained unchanged for over two decades, delaying or deterring new medicine launches. Raising it is viewed as vital to attracting foreign investment, expanding patient access, and maintaining the UK’s global standing in life sciences.
Guy Oliver, General Manager for Bristol Myers Squibb UK and Ireland, noted that " the current VPAG rate is leaving UK patients behind other countries, forcing cuts to NHS partnerships, clinical trials, and workforce despite government growth ambitions".
Reeves’ push for reform, supported by the ABPI’s Competitiveness Framework, underlines Britain’s intent to stay a leading hub for pharmaceutical innovation while ensuring NHS patients will gain faster access to new treatments.
By clicking the 'Subscribe’, you agree to receive our newsletter, marketing communications and industry
partners/sponsors sharing promotional product information via email and print communication from Garavi Gujarat
Publications Ltd and subsidiaries. You have the right to withdraw your consent at any time by clicking the
unsubscribe link in our emails. We will use your email address to personalize our communications and send you
relevant offers. Your data will be stored up to 30 days after unsubscribing.
Contact us at data@amg.biz to see how we manage and store your data.